Titan Pharmaceuticals Valuation
| TTNP Stock | USD 4.19 0.54 14.79% |
At this time, the company appears to be overvalued. Titan Pharmaceuticals has a current Real Value of $3.3 per share. The regular price of the company is $4.19. Our model measures the value of Titan Pharmaceuticals from inspecting the company fundamentals such as Shares Owned By Institutions of 1.85 %, shares outstanding of 914.23 K, and Return On Equity of -3.69 as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Titan Pharmaceuticals' price fluctuation is very risky at this time. Calculation of the real value of Titan Pharmaceuticals is based on 3 months time horizon. Increasing Titan Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Titan Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 4.19, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.19 | Real 3.3 | Hype 4.19 |
The intrinsic value of Titan Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Titan Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Titan Pharmaceuticals helps investors to forecast how Titan stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Titan Pharmaceuticals more accurately as focusing exclusively on Titan Pharmaceuticals' fundamentals will not take into account other important factors: Titan Pharmaceuticals Total Value Analysis
Titan Pharmaceuticals is at this time estimated to have valuation of (2.42 M) with market capitalization of 3.34 M, debt of 483 K, and cash on hands of 6.42 M. The negative valuation of Titan Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Titan Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(2.42 M) | 3.34 M | 483 K | 6.42 M |
Titan Pharmaceuticals Investor Information
About 45.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.52. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Titan Pharmaceuticals recorded a loss per share of 6.64. The entity last dividend was issued on the 1st of December 2020. The firm had 1:20 split on the 9th of January 2024. Based on the key indicators related to Titan Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Titan Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Titan Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Titan Pharmaceuticals has an asset utilization ratio of 0.1 percent. This connotes that the Company is making $0.001026 for each dollar of assets. An increasing asset utilization means that Titan Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Titan Pharmaceuticals Ownership Allocation
Titan Pharmaceuticals maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.Titan Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 3 K. Net Loss for the year was (4.71 M) with loss before overhead, payroll, taxes, and interest of (4.37 M).About Titan Pharmaceuticals Valuation
The stock valuation mechanism determines Titan Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Titan Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Titan Pharmaceuticals. We calculate exposure to Titan Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Titan Pharmaceuticals's related companies.Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. The company was incorporated in 1992 and is based in South San Francisco, California. Titan Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people.
Titan Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Titan Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 899 K | |
| Shares Float | 700.1 K |
Additional Tools for Titan Stock Analysis
When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.